Synopsis:
The company promoter, Akshay Arora, proposes to sell a 3.42% stake in the company via OFS at the floor price of Rs. 675/ share.
The shares of the Pharma company, specializing in manufacturing and supplying pharmaceutical and healthcare ingredients and intermediates, are in focus following the promoter’s proposal to sell a stake in the company.
With a market capitalization of Rs. 12,505.12 crores on Wednesday, the shares of Blue Jet Healthcare Ltd declined by 3.7 percent after making a low of Rs. 703.65 compared to its previous closing price of Rs. 731.30.
What Happened
Blue Jet Healthcare Ltd, engaged in manufacturing and supplying pharmaceutical and healthcare ingredients and intermediates, has informed that Akshay Bansarilal Arora, a promoter of Blue Jet Healthcare Limited, intends to sell up to 5,925,925 equity shares (3.42% of the total share capital) of the company through an Offer for Sale (OFS) at the floor price of Rs. 675/ share.
The sale will occur in two phases: on September 10, 2025 (T Day) for non-retail investors and on September 11, 2025 (T+1 Day) for retail investors and non-retail investors who wish to carry forward their unallocated bids from T Day.
Additionally, there is an Oversubscription Option to sell another 5,925,925 shares, which could bring the total offer size to 6.83% of the company’s equity. This Offer is being conducted to ensure compliance with the minimum public shareholding requirement as per SEBI regulations.
The Seller has appointed ICICI Securities, Kotak Securities, Motilal Oswal Financial Services, and Nomura Financial Advisory and Securities as brokers, and the transaction will take place through a designated window on the BSE and NSE. The NSE is the designated stock exchange, and NSE Clearing Limited is the clearing corporation. Interested bidders and their brokers must read this notice and follow the OFS Guidelines for participation.
Financials & Others
The company’s revenue rose by 118 percent from Rs. 163 crore to Rs. 355 crore in Q1FY25-26. Meanwhile, the Net profit rose from Rs. 38 crore to Rs. 91 crore during the same period.
The company has a strong track record of returns, with a 3-year average ROE of 26.8%, a ROCE of 39.8%, and a current ROE of 30.2%, indicating efficient use of equity and capital to generate profits. The company has a diverse product range and strong customer relationships across key categories:
Contrast Media Intermediates: The company produces agents used in medical imaging (X-rays, CT, and MRI scans) to enhance body visibility. It supplies both critical starting intermediates and advanced intermediates. With 19 products commercialized, this category contributes 39.4% to revenue.
High Intensity Sweeteners: The company focuses on developing and marketing sweeteners like saccharin and its salts for various products, including beverages, pharmaceuticals, food supplements, and animal feed. 4 products have been commercialized, contributing 13% to revenue. They serve over 300 customers globally, including marquee customers in the FMCG and agrochemical sectors.
Pharma Intermediates & APIs: The company collaborates with pharmaceutical companies to provide intermediates and active pharmaceutical ingredients (APIs) for chronic therapeutic areas, such as cardiovascular and oncology. 28 products have been commercialized, contributing 45.1% to revenue. These products are primarily marketed in regulated markets, with over 56 customers globally, including 40 in India.
Written by Sridhar J
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
